On 12/27/23, Zevra Therapeutics Inc (NASDAQ: ZVRA) stock enjoyed a major increase of 10.7%, closing at $5.48. Moreover, exceptionally high trading volume at 317% of normal accompanied the advance. The stock has risen 14.2% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ZVRA is expected to continue to be Value Creation neutral.
Zevra Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Zevra Therapeutics has a poor Power Rating of 30 and a very low Appreciation Score of 4, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment